J9017 HCPCS Level II code: Injection, arsenic trioxide, 1 mg
J9017 is the HCPCS code for “Injection, arsenic trioxide, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9017Injection, arsenic trioxide, 1 mg
Short description: Arsenic trioxide injection
HCPCS · United States
Medicare details
The indicators CMS publishes with J9017 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Jan 1, 2002
Where J9017 sits
- 1J codesDrugs administered other than orally
- 2Active code J9017Injection, arsenic trioxide, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9017 mean?
J9017 is the HCPCS code for “Injection, arsenic trioxide, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9017?
CMS lists J9017’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9017
All J codesJ8999Prescription drug, oral, chemotherapeutic, nosJ9000Injection, doxorubicin hydrochloride, 10 mgJ9003Leuprolide injectable (camcevi etm), 1 mgJ9010Injection, alemtuzumab, 10 mgJ9011Injection, datopotamab deruxtecan-dlnk, 1 mgJ9015Injection, aldesleukin, per single use vialJ9019Injection, asparaginase (erwinaze), 1,000 iuJ9020Injection, asparaginase, not otherwise specified, 10,000 unitsJ9021Injection, asparaginase, recombinant, (rylaze), 0.1 mgJ9022Injection, atezolizumab, 10 mgJ9023Injection, avelumab, 10 mgJ9024Injection, atezolizumab, 5 mg and hyaluronidase-tqjs